Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions

Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions Multiple myeloma (MM) remains incurable due to relapse, although the use of proteasome inhibitors, immunomodulatory drugs, CD38-targeting antibodies, and autologous stem cell transplantation (auto-SCT) significantly improve the clinical outcomes of patients with newly diagnosed MM. In recent years, the introduction of chimeric antigen receptor T-cell (CAR T-cell) therapy has brought hope to patients with refractory and relapsed MM. The graft-versus-myeloma effect of allogeneic SCT provides the possibility for curing a subset of MM patients. In this review, we summarize the recent advances and challenges of cellular immunotherapies for MM, focusing on auto-SCT, allogeneic SCT, and CAR T-cell approaches. We also discuss future directions, and propose a specific algorithm for cellular therapies for MM and probability of minimal residual disease-directed therapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions

Download PDF
19 pages

Loading next page...
 
/lp/springer-journals/cellular-immunotherapies-for-multiple-myeloma-current-status-awRjcfmV52
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2022
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-022-00186-4
Publisher site
See Article on Publisher Site

Abstract

Multiple myeloma (MM) remains incurable due to relapse, although the use of proteasome inhibitors, immunomodulatory drugs, CD38-targeting antibodies, and autologous stem cell transplantation (auto-SCT) significantly improve the clinical outcomes of patients with newly diagnosed MM. In recent years, the introduction of chimeric antigen receptor T-cell (CAR T-cell) therapy has brought hope to patients with refractory and relapsed MM. The graft-versus-myeloma effect of allogeneic SCT provides the possibility for curing a subset of MM patients. In this review, we summarize the recent advances and challenges of cellular immunotherapies for MM, focusing on auto-SCT, allogeneic SCT, and CAR T-cell approaches. We also discuss future directions, and propose a specific algorithm for cellular therapies for MM and probability of minimal residual disease-directed therapy.

Journal

Oncology and Therapy – Springer Journals

Published: Jun 1, 2022

Keywords: Multiple myeloma; Autologous stem cell transplantation; Allogeneic stem cell transplantation; Chimeric antigen receptor T cell; Relapse

References

  • Multiple myeloma
    van de Donk, NWCJ; Pawlyn, C; Yong, KL
  • Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up(dagger)
    Dimopoulos, MA; Moreau, P; Terpos, E
  • Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for haematology/UK myeloma forum guideline
    Sive, J; Cuthill, K; Hunter, H
  • Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline
    Mikhael, J; Ismaila, N; Cheung, MC
  • Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial
    Stadtmauer, EA; Pasquini, MC; Blackwell, B
  • A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma
    Wang, D; Wang, J; Hu, G
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial
    Diamond, B; Korde, N; Lesokhin, AM
  • Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial
    Roussel, M; Moreau, P; Hebraud, B
  • Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study
    Tacchetti, P; Pantani, L; Patriarca, F
  • Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial
    Usmani, SZ; Hoering, A; Ailawadhi, S
  • Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
    Facon, T; Kumar, SK; Plesner, T
  • Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
    Moreau, P; Hulin, C; Perrot, A
  • Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older
    Munshi, PN; Vesole, DH; St Martin, A
  • Development of CAR-T cell therapies for multiple myeloma
    Gagelmann, N; Riecken, K; Wolschke, C
  • Sequential CD19 and BCMA-specific CAR T cell treatment elicits sustained remission of relapsed and/or refractory myeloma
    Yan, L; Qu, S; Shang, J
  • Idecabtagene vicleucel in relapsed and refractory multiple myeloma
    Munshi, NC; Anderson, LD; Shah, N
  • Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
    Berdeja, JG; Madduri, D; Usmani, SZ
  • Risk factors associated with durable progression-free survival in patients with relapsed or refractory multiple myeloma treated with anti-BCMA CAR T cell therapy
    Zhang, M; Zhou, L; Zhao, H
  • A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
    Mei, H; Li, C; Jiang, H
  • Efficacy of humanized anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma patients with and without extramedullary disease
    Deng, H; Liu, M; Yuan, T
  • Anti-BCMA CAR T cell therapy bb2121 in relapsed or refractory multiple myeloma
    Raje, N; Berdeja, J; Lin, Y
  • A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
    Yan, Z; Cao, J; Cheng, H
  • Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
    Xu, J; Chen, LJ; Yang, SS
  • T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma
    Brudno, JN; Maric, I; Hartman, SD
  • A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
    Zhao, WH; Liu, J; Wang, BY
  • Long-term outcome after allogeneic stem cell transplantation in multiple myeloma
    Luoma, S; Silvennoinen, R; Rauhala, A
  • Post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis in multiple myeloma patients who underwent allogeneic hematopoietic cell transplantation: first comparison by donor type. A study from the chronic malignancies working party of the European Society for Blood and Marrow Transplantation
    Sahebi, F; Eikema, DJ; Koster, L
  • Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT
    Gagelmann, N; Eikema, DJ; de Wreede, LC
  • Second allogeneic transplants for multiple myeloma: a report from the EBMT chronic malignancies working party
    Hayden, PJ; Eikema, DJ; de Wreede, LC
  • Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation
    Costa, LJ; Iacobelli, S; Pasquini, MC
  • Long-term follow-up of CALGB (alliance) 100001: autologous followed by nonmyeloablative allogeneic transplant for multiple myeloma
    Holstein, SA; Suman, VJ; Owzar, K
  • Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis
    Knop, S; Engelhardt, M; Liebisch, P
  • Outcomes of haploidentical transplantation in patients with relapsed multiple myeloma: an EBMT/CIBMTR report
    Sahebi, F; Garderet, L; Kanate, AS
  • Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life
    Greil, C; Engelhardt, M; Ihorst, G
  • Myeloma escape after stem cell transplantation is a consequence of T cell exhaustion and is prevented by TIGIT blockade
    Minnie, SA; Kuns, RD; Gartlan, KH
  • Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
    Paiva, B; Cedena, MT; Puig, N
  • Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity
    Diamond, BT; Rustad, E; Maclachlan, K
  • Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and/or refractory multiple myeloma: analysis of POLLUX and CASTOR
    Avet-Loiseau, H; San-Miguel, J; Casneuf, T
  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
    Kumar, S; Paiva, B; Anderson, KC
  • Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
    Cavo, M; Gay, F; Beksac, M
  • Autologous stem-cell transplantation for multiple myeloma in the era of novel therapies
    Parrondo, RD; Ailawadhi, S; Sher, T; Chanan-Khan, AA; Roy, V
  • Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?
    Barosi, G; Gale, RP
  • Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma
    Goldschmidt, H; Dimopoulos, MA; Rajkumar, SV
  • Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
    Goldschmidt, H; Mai, EK; Durig, J
  • Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
    Voorhees, PM; Kaufman, JL; Laubach, J
  • Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
    Baertsch, MA; Mai, EK; Hielscher, T
  • Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma
    Bygrave, C; Pawlyn, C; Davies, F
  • Mortality from multiple myeloma within one year following autologous stem cell transplantation: defining an ultra-high risk population
    Cherniawsky, HM; AlAhwal, H; Mourad, YA
  • Tandem autologous hematopoietic cell transplantation with sequential use of total marrow irradiation and high-dose melphalan in multiple myeloma
    Giebel, S; Sobczyk-Kruszelnicka, M; Blamek, S
  • Reduction in late mortality among patients with multiple myeloma treated with autologous peripheral blood stem cell transplantation-a blood or marrow transplant survivor study report
    Giri, S; Chen, Y; Wu, J
  • Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: a randomised phase 2 trial by the nordic myeloma study group
    Gregersen, H; Peceliunas, V; Remes, K
  • Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III
    Jackson, GH; Davies, FE; Pawlyn, C
  • Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): interim analysis of an open-label randomised controlled trial
    Jackson, GH; Pawlyn, C; Cairns, DA
  • Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma
    Lemieux, C; Muffly, LS; Iberri, DJ
  • Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
    Mai, EK; Miah, K; Bertsch, U
  • Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis
    Pasvolsky, O; Yeshurun, M; Fraser, R
  • Safety and efficacy of consolidation therapy with ipilimumab plus nivolumab after autologous stem cell transplantation
    Skarbnik, AP; Donato, ML; Feinman, R
  • Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myeloma
    Tan, JLC; Das, T; Kliman, D
  • Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
    Rosinol, L; Oriol, A; Rios, R
  • Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
    Gay, F; Musto, P; Rota-Scalabrini, D
  • Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
    Goldschmidt, H; Baertsch, MA; Schlenzka, J
  • Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
    Drayson, MT; Bowcock, S; Planche, T
  • Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
    Moreau, P; Attal, M; Hulin, C
  • Addition of isatuximab to lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed, transplant-eligible multiple myeloma patients: the phase III GMMG-HD7 trial
    Goldschmidt, H; Mai, EK; Nievergall, E
  • Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial
    Bashir, Q; Thall, PF; Milton, DR
  • Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
    Dimopoulos, MA; Gay, F; Schjesvold, F
  • Salvage autologous stem cell transplantation in daratumumab-refractory multiple myeloma
    Yarlagadda, L; Gundarlapalli, S; Parikh, R
  • Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN
    Voorhees, PM; Rodriguez, C; Reeves, B
  • Emerging immunotherapies in multiple myeloma
    Shah, UA; Mailankody, S
  • Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
    Spencer, A; Lentzsch, S; Weisel, K
  • Chimeric antigen receptor T cell therapy for multiple myeloma: a consensus statement from the European myeloma network
    Moreau, P; Sonneveld, P; Boccadoro, M
  • Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges
    Dhakal, B; Hari, PN; Usmani, SZ; Hamadani, M
  • Successful treatment of relapsed/refractory extramedullary multiple myeloma with anti-BCMA CAR-T cell therapy followed by haploidentical hematopoietic stem cell transplantation: a case report and a review of the contemporary literature
    Qian, Y; Qian, Z; Zhao, X
  • NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma
    Leivas, A; Valeri, A; Cordoba, L
  • Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
    Lonial, S; Lee, HC; Badros, A
  • A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE® (bispecific T cell engager) molecule, in relapsed/refractory (RR) multiple myeloma (MM)
    Harrison, SJ; Minnema, MC; Lee, HC
  • Granulocyte colony-stimulating factor-primed unmanipulated haploidentical blood and marrow transplantation
    Chang, YJ; Zhao, XY; Huang, XJ
  • HLA informs risk predictions after haploidentical stem cell transplantation with post-transplantation cyclophosphamide
    Fuchs, EJ; McCurdy, SR; Solomon, SR
  • Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors
    Van Elssen, C; van Gorkom, G; Voorter, C
  • The global state of hematopoietic cell transplantation for multiple myeloma: an analysis of the worldwide network of blood and marrow transplantation database and the global burden of disease study
    Cowan, AJ; Baldomero, H; Atsuta, Y
  • Prognostic factors for postrelapse survival after ex vivo CD34(+)-selected (T Cell-Depleted) allogeneic hematopoietic cell transplantation in multiple myeloma
    Gomez-Arteaga, A; Shah, GL; Baser, RE
  • Long-term results of prophylactic donor lymphocyte infusions for patients with multiple myeloma after allogeneic stem cell transplantation
    Groger, M; Gagelmann, N; Wolschke, C
  • Autologous/allogeneic hematopoietic cell transplantation versus tandem autologous transplantation for multiple myeloma: comparison of long-term postrelapse survival
    Htut, M; D'Souza, A; Krishnan, A
  • The role of allogeneic transplantation for multiple myeloma in the era of novel agents: a study from the Japanese society of myeloma
    Kawamura, K; Tsukada, N; Kanda, Y
  • Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
    Goldschmidt, H; Lokhorst, HM; Mai, EK
  • Progression signature underlies clonal evolution and dissemination of multiple myeloma
    Shen, YJ; Mishima, Y; Shi, J
  • Bone marrow mesenchymal stromal cells can render multiple myeloma cells resistant to cytotoxic machinery of CAR T cells through inhibition of apoptosis
    Holthof, LC; van der Schans, JJ; Katsarou, A
  • gamma-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
    Pont, MJ; Hill, T; Cole, GO
  • CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
    Radhakrishnan, SV; Luetkens, T; Scherer, SD
  • Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
    Zah, E; Nam, E; Bhuvan, V
  • Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma
    Da Via, MC; Dietrich, O; Truger, M
  • Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
    Samur, MK; Fulciniti, M; Aktas Samur, A
  • CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
    Hamieh, M; Dobrin, A; Cabriolu, A
  • Blockade of AIM2 inflammasome or alpha1-AR ameliorates IL-1beta release and macrophage-mediated immunosuppression induced by CAR-T treatment
    Liu, D; Xu, X; Dai, Y
  • Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7
    Amatya, C; Pegues, MA; Lam, N
  • Preclinical development of CD126 CAR-T cells with broad antitumor activity
    Mishra, AK; Kemler, I; Dingli, D
  • CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free sleeping beauty gene transfer to treat multiple myeloma
    Prommersberger, S; Reiser, M; Beckmann, J
  • Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma
    Schmidts, A; Ormhoj, M; Choi, BD
  • Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma
    Martinez-Lopez, J; Alonso, R; Wong, SW
  • Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial
    Yang, W; Cai, J; Shen, S
  • Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma
    Patel, DA; Gopalakrishnan, R; Engelhardt, BG
  • Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
    Oliva, S; Bruinink, DHO; Rihova, L
  • Clinical applications and future directions of minimal residual disease testing in multiple myeloma
    Oliva, S; D'Agostino, M; Boccadoro, M; Larocca, A
  • Improving outcomes for patients with relapsed multiple myeloma: challenges and considerations of current and emerging treatment options
    Ramasamy, K; Gay, F; Weisel, K; Zweegman, S; Mateos, MV; Richardson, P
  • Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
    Usmani, SZ; Garfall, AL; van de Donk, N
  • Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
    Garfall, AL; Stadtmauer, EA; Hwang, WT
  • Sequential CD19/22 CAR T cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma
    Wu, J; Meng, F; Cao, Y
  • Bi38-3 is a novel CD38/CD3 bispecific T cell engager with low toxicity for the treatment of multiple myeloma
    Fayon, M; Martinez-Cingolani, C; Abecassis, A